Opinion|Videos|March 27, 2024
The Role of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Advertisement
Advertisement
Related to this article
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
5